Cationic polymers for enhancing CpG oligodeoxynucleotides-mediated cancer immunotherapy

Fu, Jingru; Cai, Jinguang; Ling, Guixia; Li, Anning; Zhao, Jiawei; Guo, Xingjie; Zhang, Peng

doi:10.1016/j.eurpolymj.2018.12.044

Cited by 13 publications

(8 citation statements)

References 122 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, conjugation with polycationic enhances APCs uptake, prolongs half‐life, and prevents degradation of CpG‐ODNs. [ 422 ]…”

Section: Nonviral Gene Therapy Systemsmentioning

confidence: 99%

“…[ 423 ] Today, they have been used in clinical trials for treatment of the cancers including malignant glioblastoma, melanoma, wilms tumor 1, basal cell carcinoma, germ cell tumor, B‐cell chronic lymphocytic leukemia (B‐CLL), colon, pancreatic, rectal, lung, cervical, epithelioid, papilla, breast, esophageal, prostate and ovarian cancers (Table 7). [ 414,422,424 ] Furthermore, about 20 CPG‐ODN adjuvants combined with corresponding vaccines are in clinical trials for the treatment of infectious diseases including malaria, influenza, pneumococcus in HIV‐infected adults, hookworm infections, cytomegalovirus infections, anthrax, and hepatitis B. [ 414 ]…”

Section: Nonviral Gene Therapy Systemsmentioning

confidence: 99%

See 1 more Smart Citation

Engineering Gene Therapy: Advances and Barriers

Shahryari

Burtscher

Nazari

et al. 2021

Advanced Therapeutics

View full text Add to dashboard Cite

Currently, 33 gene‐therapy drugs/products have been approved in the clinic. Over 3000 completed and ongoing clinical gene therapy trials have been reported worldwide. The development/maturation of tools for gene manipulation and gene delivery, as well as molecular advances in the diagnosis of genetic diseases, have played a central role in gene therapy, which have greatly revolutionized the field. Versatile and diverse genetic tools for gene manipulations and deliveries, with the possibility of short and long‐term effects, are vital advantages of gene therapy tools, paving the road for the development of new therapies. However, efficacy and safety concerns, immune system responses, laborious approaches for developing and manufacturing, unknown gene‐therapy drug interactions with the host and the high cost of drugs/products, are significant barriers in gene therapy. Here, the authors review the attempts for engineering of the gene manipulations that have been undertaken in the last three decades and used in clinical trials focusing on 1) gene‐editing platforms, 2) viral gene delivery systems, and 3) nonviral gene tools. In this comprehensive review, the principles of these gene manipulation tools as well as advances and barriers for their application in modern therapies are discussed. Furthermore, trends and future directions in gene therapy are discussed.

show abstract

“…Furthermore, conjugation with polycationic enhances APCs uptake, prolongs half‐life, and prevents degradation of CpG‐ODNs. [ 422 ]…”

Section: Nonviral Gene Therapy Systemsmentioning

confidence: 99%

Section: Nonviral Gene Therapy Systemsmentioning

confidence: 99%

Engineering Gene Therapy: Advances and Barriers

Shahryari

Burtscher

Nazari

et al. 2021

Advanced Therapeutics

View full text Add to dashboard Cite

show abstract

“…In humans and other mammals, TLR9 is expressed on B cells and plasmacytoid dendritic cells (pDCs), and it can recognize CpG. 11 Poly I:C is structurally similar to double-stranded RNA (found in some viruses) and binds to the TLR3 which is expressed on the membranes of B cells, macrophages, and dendritic cells. 12 CD40 is an immune-stimulating protein expressed on the surface of immune cells such as dendritic and B cells.…”

Section: Introductionmentioning

confidence: 99%

Mannan and anti-CD40 antibody decorated and tumor antigen, CpG and Poly I:C encapsulated poly lactic-co- glycolic acid (PLGA) nanoparticles loaded dendritic cells induced type I immune responses against prostate cancer ex vivo

Ziamiavaghi,

Delirezh,

Sheikhzadeh

2023

Preprint

View full text Add to dashboard Cite

Purpose Cancer vaccines that stimulate the immune system to detect tumor-related antigens and trigger a T cell response have shown remarkable success in prostate cancer immunotherapy. In this study, we used PLGA nanoparticles and a carrier to deliver TCL, CPG-ODN, and Poly I:C to dendritic cells. We engineered the surface of the nanoparticles with mannan and anti-CD40 antibodies to specialize TCL delivery to dendric cells. We estimated different molecules and adjuvants' effects on DCs and T cell activation. Method In this study, Poly lactic-co-glycolic acid (PLGA) nanoparticles encapsulated with LNCaP cell line tumor antigens as well as Polyinosinic: polycytidylic acid (Poly: IC) and CpG-ODN as adjuvants. Mannan (MN) and Anti-CD40 antibody were then attached to the surface of PLGA nanoparticles. Monocyte-derived dendritic cells were generated, and on day 4, tumor cell lysate (TCL) and 8 different groups of nanoparticles were added to DCs to stimulate T lymphocytes and measure T cell response in vitro. Result Our results showed that using TCL, CpG-ODN, and Poly I:C encapsulated in nanoparticles and decorating the surface of nanoparticles with Mannan and anti-CD40 can induce maturation of dendritic cells and stimulate strong antitumor immune responses as well. Conclusion Therefore, combining TCL and adjuvants within nanoparticles and decorating them with Mannan and anti-CD40 enhances antitumor immune responses and can be considered an effective treatment strategy in prostate cancer.

show abstract

“…These polymeric systems obtain various advantages including superior biocompatibility and biodegradability, effective activity for immune stimulation, tunable size, designable structure, and large loading capacity for immune-inducing factors (39)(40)(41)(42)(43). Moreover, advanced polymeric systems with different functions can be utilized to carry immune pharmaceuticals to targeting organs by different routes of administration such as subcutaneously, intranasally, and intravenously (44)(45)(46)(47). To elaborate, these pharmaceutical drugs are delivered through polymeric systems in various forms such as polymer-drug conjugates or drug-loaded micelles (48,49).…”

Section: Introductionmentioning

confidence: 99%

Polymeric Systems for Cancer Immunotherapy: A Review

Le¹,

Yoon²,

Thambi³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Immunotherapy holds enormous promise to create a new outlook of cancer therapy by eliminating tumors via activation of the immune system. In immunotherapy, polymeric systems play a significant role in improving antitumor efficacy and safety profile. Polymeric systems possess many favorable properties, including magnificent biocompatibility and biodegradability, structural and component diversity, easy and controllable fabrication, and high loading capacity for immune-related substances. These properties allow polymeric systems to perform multiple functions in immunotherapy, such as immune stimulants, modifying and activating T cells, delivery system for immune cargos, or as an artificial antigen-presenting cell. Among diverse immunotherapies, immune checkpoint inhibitors, chimeric antigen receptor (CAR) T cell, and oncolytic virus recently have been dramatically investigated for their remarkable success in clinical trials. In this report, we review the monotherapy status of immune checkpoint inhibitors, CAR-T cell, and oncolytic virus, and their current combination strategies with diverse polymeric systems.

show abstract

Cationic polymers for enhancing CpG oligodeoxynucleotides-mediated cancer immunotherapy

Cited by 13 publications

References 122 publications

Engineering Gene Therapy: Advances and Barriers

Engineering Gene Therapy: Advances and Barriers

Mannan and anti-CD40 antibody decorated and tumor antigen, CpG and Poly I:C encapsulated poly lactic-co- glycolic acid (PLGA) nanoparticles loaded dendritic cells induced type I immune responses against prostate cancer ex vivo

Polymeric Systems for Cancer Immunotherapy: A Review

Contact Info

Product

Resources

About